Drugs / ABT-493/ABT-530
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT02446717 | Apr 2015 → Dec 2016 | chronic hepatitis C virus infection | AbbVie | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-493/ABT-530 | “ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD)” NCT02446717 ↗ |